Participant demographics and baseline characteristics
| Parameter | Value | 25 mg | 50 mg | Overall (n=58) | |||
| PDAC (n=18) | MSS mCRC (n=33) | Other (n=4) | Total (n=55) | (n=3) | |||
| Gender (n (%)) | Male | 8 (44.4) | 16 (48.5) | 2 (50.0) | 26 (47.3) | 1 (33.3) | 27 (46.6) |
| Race (n (%)) | White/Caucasian | 15 (83.3) | 28 (84.8) | 3 (75.0) | 46 (83.6) | 2 (66.7) | 48 (82.8) |
| Asian/Oriental | 3 (16.7) | 4 (12.1) | 1 (25.0) | 8 (14.5) | 1 (33.3) | 9 (15.5) | |
| Other | 0 (0.0) | 1 (3.0) | 0 (0.0) | 1 (1.8) | 0 (0.0) | 1 (1.7) | |
| Age (year) | Median | 62.00 | 58.00 | 60.00 | 60.00 | 74.00 | 60.00 |
| Min | 45.0 | 35.0 | 53.0 | 35.0 | 44.0 | 35.0 | |
| Max | 71.0 | 80.0 | 66.0 | 80.0 | 78.0 | 80.0 | |
| Min | 43.7 | 47.2 | 47.9 | 43.7 | 56.6 | 43.7 | |
| ECOG, n (%) | 0 | 8 (44.4) | 22 (66.7) | 1 (25.0) | 31 (56.4) | 0 (0.0) | 31 (53.4) |
| 1 | 10 (55.6) | 11 (33.3) | 3 (75.0) | 24 (43.6) | 3 (100.0) | 27 (46.6) | |
| Disease stage, n (%) | Locally advanced | 1 (5.6) | 0 (0.0) | 0 (0.0) | 1 (1.8) | 0 (0.0) | 1 (1.7) |
| Metastatic disease | 17 (94.4) | 33 (100.0) | 4 (100.0) | 54 (98.2) | 3 (100.0) | 57 (98.3) | |
| BRAF status, n (%) | Wild-type | 12 (36.4) | |||||
| Unknown | 21 (63.6) | ||||||
| Primary tumor location, n (%) | Right sided | 7 (21.1) | |||||
| Left sided | 7 (21.1)* | ||||||
| Rectum | 20 (60.6)* | ||||||
| KRAS status, n (%) | Mutated | 14 (42.4) | |||||
| Wild-type | 11 (33.3) | ||||||
| Unknown | 8 (24.2) | ||||||
| NRAS status, n (%) | Mutated | 3 (9.1) | |||||
| Wild-type | 10 (30.3) | ||||||
| Unknown | 20 (60.6) | ||||||
| Prior therapy, n (%) | Chemotherapy | 18 (100) | 33 (100) | 4 (100) | 55 (100) | 2 (66.7) | 57 (98.3) |
| Radiotherapy | 3 (16.7) | 9 (27.3) | 2 (50.0) | 14 (25.5) | 1 (33.3) | 15 (25.9) | |
| Targeted therapy | 0 (0.0) | 7 (21.2) | 0 (0.0) | 7 (12.7) | 0 (0.0) | 7 (12.1) | |
*One participant had primary tumor recorded as both left sided and rectum.
ECOG, Eastern Cooperative Oncology Group.